Early ultrasound-guided thoracic paravertebral block reduces postherpetic neuralgia incidence in acute herpes zoster patients
In a randomized clinical trial of 100 patients with acute thoracic herpes zoster, adding ultrasound-guided thoracic paravertebral block (TPVB) with bupivacaine and methylprednisolone to standard therapy significantly reduced the incidence of postherpetic neuralgia at 90 days (16% vs. 34%, P=0.037). The TPVB group also showed improved pain scores, quality of life, sleep quality, and functional disability at 3 and 6 months.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Early ultrasound-guided thoracic paravertebral block reduces postherpetic neuralgia incidence in acute herpes zoster patients The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Early ultrasound-guided thoracic paravertebral block reduces postherpetic neuralgia incidence in acute herpes zoster patients
This conclusion is most relevant to: 100 patients with acute thoracic herpes zoster (rash duration ≤14 days, NRS ≥4).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Early ultrasound-guided thoracic paravertebral block reduces postherpetic neuralgia and improves functional outcomes in acute herpes zoster: a randomized clinical trial. (Revista espanola de anestesiologia y reanimacion, 2026) —
How It Works
The proposed biological pathway:
- ▸Local anesthetic blocks nociceptive input from affected dorsal root ganglia
- ▸Corticosteroid reduces inflammation and neural damage
- ▸Early intervention prevents central sensitization and chronic pain pathways
- ▸Result: Reduced incidence of postherpetic neuralgia and improved functional outcomes
Who Might Benefit
Evidence fit by population:
- ▸100 patients with acute thoracic herpes zoster (rash duration ≤14 days, NRS ≥4)
Recommended Dose
40 mg methylprednisolone per block, three sessions
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Single-center study with relatively small sample size (n=100)
- ▸No sham or placebo block in the control group, limiting blinding
- ▸Follow-up limited to 6 months; longer-term durability of effect not assessed
Frequently Asked Questions
How does early TPVB reduce the risk of postherpetic neuralgia?▼
By blocking nociceptive input and reducing inflammation early in the acute phase, TPVB may prevent central sensitization and chronic pain development.
What are the key benefits of TPVB beyond pain relief?▼
The study found significant improvements in sleep quality (PSQI), functional disability (PDI), and overall quality of life (SF-36) at 3 and 6 months.
Is TPVB safe for acute herpes zoster patients?▼
No serious block-related complications were reported, suggesting it is a safe adjunctive therapy when performed under ultrasound guidance.
How long after rash onset should TPVB be performed?▼
The study included patients with rash duration ≤14 days, and blocks were performed at 48-hour intervals for three sessions, indicating early intervention is key.
References
- 1.Mahmoud Abdallah AO, Abdelrady MM, Omar Mahmoud H, Mohamed Hasan Eisa MA. “Early ultrasound-guided thoracic paravertebral block reduces postherpetic neuralgia and improves functional outcomes in acute herpes zoster: a randomized clinical trial..” Revista espanola de anestesiologia y reanimacion, 2026. PMID: 42431311 DOI: 10.1016/j.redare.2026.502176